– Intranasal administration of NL-CVX1 protects hamsters from lethal SARS-CoV-2 infection –
– Designed to resist viral mutational escape by mimicking the natural target of the spike protein –
SEATTLE, Nov. 05, 2020 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2. This report details the creation of de novo protein decoys that were specifically designed to bind the SARS-CoV-2 spike protein with high affinity, preventing its association with the viral receptor hACE2, which is required for infection. The manuscript titled “De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2” is available online here1 via Science First Release.
As reported, the optimized, hyperstable proteins act